New risk score predicts recurrence in liver transplant for cancer

A novel risk score, PRETREAT, was developed to estimate post-transplant recurrence in patients with perihilar cholangiocarcinoma (pcca) following neoadjuvant therapy and liver transplantation. In a study involving 399 patients, the five-year recurrence rate was 29.7% in the development cohort and 27.6% in the validation cohort. Four predictors—residual tumor, vascular encasement, lymphovascular invasion, and tumor diameter—were identified. The PRETREAT score demonstrated excellent predictive performance, significantly stratifying patients into low, moderate, and high-risk groups.